Laurus Labs Ltd, a leading research and fully integrated pharmaceutical company in India, on March 26 announce that the Company has entered into a strategic partnership agreement with Global Fund for a period of about three years for the treatment of HIV/AIDS.

Under this long term Partnership agreement, Laurus Labs received and executed the order from Global Fund which would cater to the supplies of the high burden diseases countries in Sub Saharan African (SSA) region. This is the first maiden order for Tenofovir/Lamivudine/Dolutegravir 300/300/50mg (TLD) after the received a tentative approval from USFDA in the month of February 2019.

Commenting on the agreement, Laurus Founder and CEO, Dr Satyanarayana Chava, said, "We’re greatly encouraged by the strategic partnership agreement with Global Fund and also the maiden order for Laurus Labs from Global Fund. We thank Global Fund team for placing its trust for a new entrant like us in ARV – FDF space.

For Laurus Labs, it is a very significant development which has ventured into the FDFs couple of years ago and this partnership has increased the company’s commitment to contribute to the global mission for treating millions of HIV AIDS patients across the globe", he added.

The Company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C.

Laurus also manufactures APIs in Oncology and other therapeutic areas. The company has also ventured into develop a Finished Dosages Forms on the back of existing strengths in APIs with a current capacity of 5 billion units per year, expandable up to 8 billion units per year.